Stockreport

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months [Yahoo! Finance]

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension - The continued curve separation of the composite endp [Read more]